AzTrials
AzTrials

NephrolithiasisNCT01650935

Comparison of DASH With Oxalate Restricted Diet on Urine in Recurrent Stone Formers With Hyperoxaluria

A study testing diet in people with Nephrolithiasis, run by Shahid Beheshti University of Medical Sciences at 2 sites in Iran.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Oxalate restricted diet is routinely prescribed in clinical practice of nephrolithiasis patients with hyperoxaluria. The effect of dietary oxalate on urinary oxalate is however controversial. Some studies do not implicate dietary oxalate as a major risk factor for nephrolithiasis. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Nephrolithiasis
What is being tested?
diet
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
2 sitesIran
Study dates
Sep 2012to Apr 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • A history of at least one time kidney stone
  • more than 18 years old
  • stones at least 50% calcium oxalate
  • normal renal function, -sterile urine samples, -
  • normal blood pressure

Who cannot join

  • primary hyperoxaluria (urine oxalate>100 mg/24h)
  • diabetes mellitus
  • hepatic, thyroid, parathyroid, CKD or immunologic disease

Trial locations and contacts

2 sites in 1 country.

Iran2 sites
  • Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences

    Tehran, 1666677951

  • Labbafinejad Hospital

    Tehran, 5122

Other trials in Iran

About this study

Official title: Study of the Effects of DASH Style Diet and Oxalate Restricted Diet on Urinary Supersaturation Which is a Major Predisposing Factor for Nephrolithiasis

Oxalate restricted diet is routinely prescribed in clinical practice of nephrolithiasis patients with hyperoxaluria. The effect of dietary oxalate on urinary oxalate is however controversial. Some studies do not implicate dietary oxalate as a major risk factor for nephrolithiasis. The Dietary Approaches to Stop Hypertension (DASH) diet, which is high in fruits and vegetables, moderate in low-fat dairy products, and low in animal protein represents a novel potential means of kidney stone prevention. The effect of a DASH-style diet on relative urinary supersaturations is however uncertain. Higher consumption of fruits and vegetables may increase urinary oxalate but also increases urinary citrate, an important inhibitor of calcium saturation.All the above data lead us to hypothesize that a DASH diet other than an oxalate restricted diet, which is routinely administered in clinical practice, might be beneficial in lowering urinary relative supersaturations of calcium oxalate in recurrent stone formers with hyperoxaluria.

Recurrent stone formers with hyperoxaluria (urine oxalate>32.8) are allocated into 2 groups. The first group is prescribed an oxalate restricted diet. The second group are asked to follow a calorie-controlled DASH diet plan while drink water in the same amounts. 24-h urine is collected 2 times before study visits at baseline, 1 time on week 6 and 2 times at the end of the study.

Read the detailed description

After a run-in period of 3 weeks patients are allocated into 2 groups. The first group is prescribed an oxalate restricted diet. They are instructed to avoid oxalate-rich foods such as spinach, rhubarb, beets, chocolate, cereals, nuts, tea, wheat bran, and strawberries and to drink water in amounts of roughly 2 L during cold weather and 3 L during warm/hot weather. The second group is asked to follow a calorie-controlled DASH diet plan. DASH is an eating pattern recommended by the 2005 Department of Health and Human Services Dietary Guidelines for Americans as a model of healthy eating for the majority of individuals in the population . This group eats a diet which includes higher fruit, vegetables, and low-fat dairy products and lower in saturated fat, total fat, and cholesterol, containing more whole grains and fewer refined grains, sweets, and red meat. The calcium, potassium, and magnesium of the DASH diet is higher. The DASH diet contains 2,400 mg Na per day . The servings, mentioned in the publication of the National Institutes of Health regarding the DASH eating plan, are used as a practical guideline. Lower consumption of meat and higher consumption of low-fat dairies, vegetable, fruit, whole-grain cereals, and legumes distinguish between the DASH trial and the weight-reduction diet.

We determine the caloric needs for each person in both groups individually according to the Harris Benedict Formula:

Metric BMR Formula Women: BMR= 655 + ( 9.6 × weight in kilos ) + ( 1.8 × height in cm ) - ( 4.7 × age in years ) Men: BMR= 66 + ( 13.7 × weight in kilos ) + ( 5 × height in cm ) - ( 6.8 × age in years )

To determine their total daily calorie needs, multiply their BMR by the appropriate activity factor, as follows:

If they are sedentary (little or no exercise) : Calorie-Calculation = BMR × 1.2 If they are lightly active (light exercise/sports 1-3 days/week) : Calorie-Calculation = BMR × 1.375 If they are moderately active (moderate exercise/sports 3-5 days/week) : Calorie-Calculation = BMR × 1.55 If they are very active (hard exercise/sports 6-7 days a week) : Calorie-Calculation = BMR × 1.725 If they are extra active (very hard exercise/sports \& physical job or 2x training) : Calorie-Calculation = BMR × 1.9

The patients are visited in the beginning, after 6 weeks and at the end of the study; each session for a patient is 45-60 min. They are in touch with the nutritionist by phone every week. The nutritionist explains the benefits of each diet for patients and tells them if they continue these diets, related metabolic abnormalities might be controlled. The diets are individually prescribed using a calorie count system, and an exchange list is given to each patient for exchanging food items and counting the calories. A nutritionist educates subjects on how to use the exchange list. Patient compliance to diet is evaluated by a detailed food recall for 3 days which are collected from 2 weekdays and 1 weekend day in week 1 and week 12 as well as evaluation of the urinary excretion of sodium, inorganic sulfate and total nitrogen. The food recalls are reviewed by a nutrition PhD when they are submitted and then are analyzed using nutritionist IV software. 24-h urine is also collected 2 times before study visits at baseline, and 2 times at the end of the study on the day food recalls are filled. Urinary supersaturation of calcium oxalate, calcium phosphate and uric acid also is calculated at the beginning and end of the study. Because this is a dietary intervention, patients are not blinded.

Clinical measurements included blood pressure, weight, height, and waist circumference. Blood pressure measurements are the average of 2 measurements and are taken using an automated system after the subjects are seated for 5 minutes. Participants are weighed wearing minimal clothing and without shoes. Height is measured in a standing position, without shoes. Waist circumference is measured where the waist is narrowest over light clothing. Body mass index (kg/m2) is calculated as weight (kg) divided by height squared (m2) We use General Linear Models (paired t tests) to globally compare means of all variables at the end of the 2 different diet periods with and without adjustment for weight. We calculate the percent change for each variable using the formula (E- B/B)×100, where E was the end of treatment value and B was the baseline value. Groups are compared using the percent change in the General Linear Model (paired t test)analyses. We use ANCOVA to compare adjusted means of end values and percent changes while weight change was included as a covariate. Results are considered significant if the 2-tailed P-value is<,0.05. Statistical analyses are performed using STATA 15.0.

Conditions
Nephrolithiasis
Being tested
diet
Keywords
Nephrolithiasis, Recurrent stone former, DASH, Urine oxalate, Urine calcium oxalate supersaturation
Medical subject headings
Nephrolithiasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • dietBehavioural

    When the first set of urine samples confirmed hyperoxaluria (urine oxalate>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study

Study groups in NCT01650935
Study groupRoleWhat they receive
Oxalate restrictedActive comparatorAfter a run-in period of 3 weeks patients are allocated into 2 groups. The Oxalate restricted group is prescribed an oxalate restricted diet. They are instructed to avoid oxalate-rich foods such as spinach, rhubarb, beets, chocolate, cereals, nuts, tea, wheat bran, and strawberries and to drink water in amounts of roughly 2 L during cold weather and 3 L during warm/hot weather.
Receives: Behavioral: diet
DASH dietActive comparatorThe second group is asked to follow a calorie-controlled DASH diet plan. DASH is an eating pattern recommended by the 2005 Department of Health and Human Services Dietary Guidelines for Americans as a model of healthy eating for the majority of individuals in the population. This group eats a diet which includes higher fruit, vegetables, and low-fat dairy products and lower in saturated fat, total fat, and cholesterol, containing more whole grains and fewer refined grains, sweets, and red meat.
Receives: Behavioral: diet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. urinary oxalate

    24-h urine including urine oxalate is collected 2 times before study visits at baseline, and 2 times at the end of the study which is 2 months.

    Measured: 2 months

Secondary outcomes (1)
  1. urinary calcium oxalate supersaturation

    Urinary supersaturation is calculated before study visits at baseline, and at the end of the study which is 2 months.

    Measured: 2 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jul 2012 (estimated)
  2. Study startSep 2012
  3. Primary completionFeb 2013
  4. Study completionApr 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
48 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01650935
Sponsor's protocol ID
114
Status last verified
Apr 2013
First submitted
24 Jul 2012
Last updated
16 Apr 2013
Results posted
No
Data monitoring committee
Yes

Publications

  • Noori N, Honarkar E, Goldfarb DS, Kalantar-Zadeh K, Taheri M, Shakhssalim N, Parvin M, Basiri A. Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets. Am J Kidney Dis. 2014 Mar;63(3):456-63. doi: 10.1053/j.ajkd.2013.11.022.

    PubMed 24560157

Questions about this trial

What is this clinical trial studying?

A study testing diet in people with Nephrolithiasis, run by Shahid Beheshti University of Medical Sciences at 2 sites in Iran.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

urinary oxalate (time frame: 2 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01650935, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in